The identification of bio-molecular pathways associated with disease is a primary goal of many basic scientists and academic researchers. These key studies have the potential to identify new molecular targets for drug discovery efforts, but it is not always clear as to which aspects of such research are patentable. In this presentation, we seek to identify patentable subject matter material and describe the requirements of patentability as they apply to products of basic research.

Come hear about obtaining patent protection around mechanisms of action of drugs associated with treatment of disease and disease-associated studies such as: genetic abnormalities; aberrant transcription factors and signaling; aberrant RNA transcription, translation, and splice variants; aberrant protein expression, post-translational modifications and folding; and aberrations in signal transduction pathways.

If possible, please RSVP to rsch-otlassistant@research.usf.edu or 813.974.6650

Reservations not required.

USF Health Byrd Alzheimer’s Institute Auditorium

Talk begins at 2:00 pm

Open to the USF Community

About Glenn Ladwig and Saliwanchik, Lloyd & Saliwanchik: Since 1981, Saliwanchik, Lloyd & Saliwanchik (SLS) has been and continues to be a pioneer in biotechnology law, having a storied history of securing intellectual property rights of inventions based on scientific research. SLS is particularly active in patent matters involving inventions that pertain to pharmaceuticals, biotechnology (plants, animals, and microbes), medical and industrial instruments, organic chemistry, electronics, software, optics, and materials science. Glenn received his law degree from Stetson University College of Law, where he graduated cum laude. In addition to an undergraduate degree in Biology from Saint Leo University, Glenn has earned master’s degrees in Medical Sciences and Pharmacy from the University of Florida, Colleges of Medicine and Pharmacy, where his graduate work focused on wound healing and forensic drug chemistry, respectively. Glenn’s clients include universities, research institutions, domestic biotech companies, and foreign corporations seeking U.S. patent protection.